Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gliadel, Radiation, Temodar, and Avastin in Newly Diagnosed GBM
NCT01186406Phase 2Terminated
- Sponsor
- Duke University
- Start
- Apr 2011
- Primary completion
- Jun 2014
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, carmustine in glioblastoma multiforme (GBM), Gliosarcoma (GS), sponsored by Duke University. Started Apr 2011; status: terminated.
02
Drugs
bevacizumabcarmustine
03
Conditions
glioblastoma multiforme (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT01186406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01186406.